La nuova combinazione di TALVEY®▼ (talquetamab) e TECVAYLI®▼ (teclistamab) comporta alti tassi di risposta e risposte durature in pazienti refrattari alla tripla classe con mieloma multiplo recidivato o refrattario, compresi i pazienti con malattia extramidollare
04. Oktober 2024 16:28 ET
|
Janssen Cilag International NV
I dati dello studio sperimentale di Fase 1b RedirecTT-1 dimostrano un profilo di sicurezza coerente con le monoterapie talquetamab e teclistamab1 BEERSE, BELGIO, Oct. 04, 2024 (GLOBE NEWSWIRE) --...
Neue Kombination aus TALVEY®▼(talquetamab) und TECVAYLI®▼ (teclistamab) deutet auf hohe Ansprechraten und ein dauerhaftes Ansprechen bei Tripe-Class-refraktären Patienten mit rezidiviertem oder refraktärem Multiplem Myelom, einschließlich Patienten mit extramedullärer Erkrankung
04. Oktober 2024 16:28 ET
|
Janssen Cilag International NV
Daten aus der Phase-Ib-Forschungsstudie RedirecTT-1 zeigen ein mit dem von talquetamab und teclistamab-Monotherapien vergleichbares Sicherheitsprofil1 BEERSE, BELGIEN, Oct. 04, 2024 (GLOBE...
La nouvelle association de TALVEY®▼ (talquétamab) et TECVAYLI®▼ (teclistamab) suggère des taux de réponse élevés et des réponses durables chez les patients réfractaires à trois classes de médicaments atteints d’un myélome multiple récidivant ou réfractaire, y compris les patients atteints d’une maladie extramédullaire
04. Oktober 2024 16:28 ET
|
Janssen Cilag International NV
Les données issues de l’étude expérimentale de Phase Ib RedirecTT-1 démontrent un profil d’innocuité cohérent avec les monothérapies par talquétamab et teclistamab1 BEERSE, BELGIQUE, 04 oct. 2024 ...
Novel combination of TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) suggest high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease
27. September 2024 08:21 ET
|
Janssen Cilag International NV
Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to talquetamab and teclistamab monotherapies1 BEERSE, BELGIUM, Sept. 27, 2024 (GLOBE NEWSWIRE) --...
Nipocalimab pivotal Phase 3 trial demonstrates sustained disease control in FcRn class for a broad population of myasthenia gravis patients
28. Juni 2024 12:09 ET
|
Janssen Cilag International NV
First FcRn blocker to demonstrate superiority in Myasthenia Gravis - Activities of Daily Living score (MG-ADL) a over placebo when added to standard of care over 24 weeks in antibody positive...
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
14. Juni 2024 03:00 ET
|
Janssen Cilag International NV
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of...
Johnson & Johnson MedTech gathers multi-disciplinary expert group to optimise lung cancer care and dialogue between patients and their healthcare team
30. Mai 2024 08:39 ET
|
Johnson & Johnson MedTech
A recent European survey revealed that 80 percent of thoracic surgeons declared to follow the Enhanced Recovery After Surgery (ERAS) protocol, focussed on improving peri-operative lung cancer care,1...
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn’s disease
01. Mai 2024 06:55 ET
|
Janssen Cilag International NV
Media contact:Sophie DaneauSdaneau@its.jnj.com+33 6 3178 8798Investor contact:Raychel Kruperinvestor-relations@its.jnj.com For European and UK medical and trade media only For immediate...
SWAV Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Shockwave Medical to Johnson & Johnson
10. April 2024 09:25 ET
|
Wohl & Fruchter LLP
We are investigating the fairness of the price of $335.00 per share in cash for which Shockwave Medical has agreed to be sold to Johnson & Johnson.
CURE Media Group and Oncology Nursing News Announces the 2024 Extraordinary Healer® Award Finalists
15. März 2024 12:00 ET
|
CURE Media Group
CRANBURY, N.J., March 15, 2024 (GLOBE NEWSWIRE) -- CURE® Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to more than 1 million patients,...